Randomized Phase II Trial of Ipilimumab (study drug) with or without Bevacizumab (study drug) in Patients with Unresectable Stage III or Stage IV Melanoma

Cancer, Cancer - Melanoma
John McCann, MD

D’Amour Center for Cancer Care
3350 Main Street
Springfield, MA 01199

Baystate Franklin Medical Center
64 High Street
Greenfield, MA

The purpose of this study is to  compare overall survival for patients with stage III or stage IV melanoma who receive ipilimumab plus bevacizumab versus ipilimumab alone.
Patients with unresectable Stage III or Stage IV Melanoma; untreated or one previous treatment.
Betsy Lopez